MVX 008

The Phase 3 follow-up study is assessing the ongoing immunogenicity of the GBS vaccine (GBS NN/NN2) previously received by pregnant women between 21-24 weeks gestational age. The study aims to evaluate immunogenicity in these women and offer a booster vaccination to women who become pregnant, with assessments of safety, reactogenicity, and immunogenicity.